Literature DB >> 7621159

Early CK-MB elevations predict ischemic events in stable chest pain patients.

J R Hedges1, G P Young, G F Henkel, W B Gibler, T R Green, J R Swanson.   

Abstract

OBJECTIVE: To demonstrate that creatine kinase-MB fraction (CK-MB) elevations within three hours of presentation in the emergency department (ED) are associated with subsequent ischemic events in clinically stable chest pain patients.
METHODS: Prospective cohort study at two university- affiliated teaching hospitals. Participants were consenting ED chest pain patients 25 years old or older without evidence of rhythm or hemodynamic instability (n = 449). Exclusions included ST-segment elevation > or = 0.1 mV in > or = 2 electrocardiogram leads, chest wall trauma, abnormal x-ray studies, and incomplete data collection. Measurements included presenting and three-hour CK-MB levels, presenting ECG, initial clinical impression of coronary care unit need, and clinical follow up. Monitored adverse events included myocardial ischemia necessitating coronary angioplasty or cardiac bypass surgery, recurrent in-hospital myocardial infarction, bradycardia requiring pacing, emergent cardioversion, cardiogenic shock, ventricular fibrillation, and death.
RESULTS: Overall, nine (2%) of 449 patients experienced an ischemic event within the first 48 hours. All nine patients required either coronary angioplasty or bypass surgery. Four (44%) of the nine patients with 48-hour ischemic events had elevated CK-MB levels. Of 23 patients who had complications within one week of ED presentation, seven (30%) had elevated ED CK-MB levels. An elevated CK-MB level was associated with an ischemic event both within 48 hours (risk ratio 9.5; 95% CI 2.7-33.7) and within one week (risk ration 5.2; 95% CI 2.3-11.7).
CONCLUSIONS: An elevated CK-MB level within three hours of ED presentation is associated with a subsequent ischemic event in the clinically stable chest pain patient without ST-segment elevation. However, the ED CK-MB identifies only a minority or otherwise low-risk patients who develop ischemic events; other markers for diagnosing myocardial ischemia in the ED are needed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7621159     DOI: 10.1111/j.1553-2712.1994.tb02794.x

Source DB:  PubMed          Journal:  Acad Emerg Med        ISSN: 1069-6563            Impact factor:   3.451


  5 in total

1.  Evaluation of a paired creatine kinase test for the diagnosis of acute myocardial infarction in patients with a non-diagnostic electrocardiogram.

Authors:  A D Hingorani; S O'Hanlon; S P Halloran; J P Wright; T H Foley
Journal:  J Accid Emerg Med       Date:  1997-05

Review 2.  The role of CK-MB in chest pain decision-making.

Authors:  J R Hedges
Journal:  J Accid Emerg Med       Date:  1995-06

3.  Pitfalls in accident and emergency chest pain evaluation.

Authors:  J R Hedges
Journal:  J R Soc Med       Date:  1995-09       Impact factor: 5.344

Review 4.  Novel Risk Stratification Assays for Acute Coronary Syndrome.

Authors:  Haitham M Ahmed; Stanley L Hazen
Journal:  Curr Cardiol Rep       Date:  2017-08       Impact factor: 2.931

5.  Novel cardiac-specific biomarkers and the cardiovascular continuum.

Authors:  Efstathios Vassiliadis; Natasha Barascuk; Athanasios Didangelos; Morten A Karsdal
Journal:  Biomark Insights       Date:  2012-05-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.